J. Frankel

发表

A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial

W. White, C. Gratzke, S. Herschorn, 2018, Blood pressure monitoring.

Cardiovascular Safety of the β3‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial

W. White, C. Gratzke, S. Herschorn, 2018, Journal of clinical pharmacology.

Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy From a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).

D. Staskin, D. Shortino, Rachael A. Jankowich, 2020, The Journal of urology.

International Phase III, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.

D. Staskin, D. Shortino, Rachael A. Jankowich, 2020, The Journal of urology.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

M. Stölzel, Jeffrey Frankel, S. Herschorn, 2013, Urology.

Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.

V. Nitti, S. Herschorn, M. B. Blauwet, 2015, European urology.

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

D. Newman, D. Staskin, D. Shortino, 2021, Advances in Therapy.

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study

D. Staskin, D. Shortino, Rachael A. Jankowich, 2020, International journal of clinical practice.

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder

D. Staskin, Rachael A. Jankowich, M. Kennelly, 2022, Therapeutics and clinical risk management.

TCRM_A_310371 171..182

D. Staskin, Rachael A. Jankowich, M. Kennelly, 2022 .

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

Susann Varano, D. Staskin, Jeffrey Frankel, 2021, Drugs & Aging.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

M. Stölzel, S. Herschorn, A. Gousse, 2013, Urology.

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

D. Newman, Susann Varano, D. Staskin, 2022, International journal of clinical practice.